Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group

Y. Schlesinger and D. M. Granoff
Mallinckrodt Department of Pediatrics, Washington University School of Medicine, St Louis, Mo.

OBJECTIVE--Antibody avidity is a measure of the functional affinity of serum antibody to bind to antigen. In this study, we compared the avidity of antibodies elicited by vaccination with three Haemophilus influenzae type b (Hib) conjugate vaccines and investigated the relationship between antibody avidity and the ability of antibody to activate complement-mediated bactericidal activity. DESIGN--A convenience sample of 171 postvaccination serum samples with more than 0.5 microgram/mL of anticapsular antibody, the minimum concentration required for measurement of avidity. The serum samples were obtained from infants participating in immunogenicity trials with Hib capsular polysaccharide (PRP) conjugated to meningococcal outer membrane protein complex (PRP-OMPC) or to tetanus toxoid (PRP-T), or PRP oligomers conjugated to a nontoxic mutant diphtheria toxin, CRM197 (Oligo-CRM). PATIENTS--Healthy infants recruited in private practices. PRIMARY OUTCOME MEASURES--Avidity of vaccine-induced serum anticapsular antibody and serum bactericidal titers. RESULTS--In infants vaccinated at 2, 4, and 6 months of age, Oligo-CRM evoked antibody of higher avidity than PRP-OMPC (P less than .001). The mean avidity of antibody elicited by PRP-T was intermediate, being lower than Oligo-CRM (P less than .02) but higher than PRP-OMPC (P = .001). Also, after one dose, 18-month-old infants given Oligo-CRM had higher avidity antibodies compared with those given PRP-OMPC (P less than .001). Half of the infants in both age groups who were given Oligo-CRM developed antibody avidity of 2.50 nM-1 or greater, whereas more than two thirds of the infants given PRP-OMPC had avidity values of 1.25 nM-1 or less. Antibodies with avidity of 1.25 nM-1 or less were, on average, 6.6-fold less active in assays of complement-mediated bactericidal activity than antibodies with avidity of 2.50 nM-1 or greater (P less than .001). CONCLUSIONS--Oligo-CRM and PRP-T conjugate vaccines elicit higher avidity antibody than PRP-OMPC, and high-avidity antibody is more potent than low-avidity antibody in serum bactericidal assays. Consideration should be given to including measurement of antibody avidity in assessment of new vaccines since avidity may affect the ability of serum antibody to confer protection against disease.

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Immunoglobulin G Avidities in Infants in Mexico after Primary Immunization with Three Doses of Polyribosylribitol Phosphate-Tetanus Toxoid Haemophilus influenzae Type b Vaccine
Gomez-de-Leon et al.
CVI 2008;15:1024-1027.
ABSTRACT | FULL TEXT  

Quality of the Haemophilus influenzae Type b (Hib) Antibody Response Induced by Diphtheria-Tetanus-Acellular Pertussis/Hib Combination Vaccines
Denoel et al.
CVI 2007;14:1362-1369.
ABSTRACT | FULL TEXT  

Functional Antibodies Elicited by Two Heptavalent Pneumococcal Conjugate Vaccines in the Finnish Otitis Media Vaccine Trial
Ekstrom et al.
Infect. Immun. 2007;75:1794-1800.
ABSTRACT | FULL TEXT  

Immunologic Response to Haemophilus influenzae Type b (Hib) Conjugate Vaccine and Risk Factors for Carriage among Hib Carriers and Noncarriers in Southwestern Alaska
Baggett et al.
CVI 2006;13:620-626.
ABSTRACT | FULL TEXT  

Avidity Determinations for Haemophilus influenzae Type b Anti-Polyribosylribitol Phosphate Antibodies
Romero-Steiner et al.
CVI 2005;12:1029-1035.
ABSTRACT | FULL TEXT  

Kinetics and Avidity of Antibodies Evoked by Heptavalent Pneumococcal Conjugate Vaccines PncCRM and PncOMPC in the Finnish Otitis Media Vaccine Trial
Ekstrom et al.
Infect. Immun. 2005;73:369-377.
ABSTRACT | FULL TEXT  

Mucosal immunology of vaccines against pathogenic nasopharyngeal bacteria
Zhang and Finn
J. Clin. Pathol. 2004;57:1015-1021.
ABSTRACT | FULL TEXT  

A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b
Verez-Bencomo et al.
Science 2004;305:522-525.
ABSTRACT | FULL TEXT  

Antibody Response to Diphtheria-Tetanus-Pertussis Immunization in Preterm Infants Who Receive Dexamethasone for Chronic Lung Disease
Robinson et al.
Pediatrics 2004;113:733-737.
ABSTRACT | FULL TEXT  

Measurement of Serum Bactericidal Activity Specific for Haemophilus influenzae Type b by Using a Chromogenic and Fluorescent Metabolic Indicator
Romero-Steiner et al.
CVI 2004;11:89-93.
ABSTRACT | FULL TEXT  

Th1-Directing Adjuvants Increase the Immunogenicity of Oligosaccharide-Protein Conjugate Vaccines Related to Streptococcus pneumoniae Type 3
Lefeber et al.
Infect. Immun. 2003;71:6915-6920.
ABSTRACT | FULL TEXT  

Enzyme-Linked Immunosorbent Assay for Quantitation of Human Antibodies to Pneumococcal Polysaccharides
Wernette et al.
CVI 2003;10:514-519.
FULL TEXT  

Age-Related Disparity in Functional Activities of Human Group C Serum Anticapsular Antibodies Elicited by Meningococcal Polysaccharide Vaccine
Harris et al.
Infect. Immun. 2003;71:275-286.
ABSTRACT | FULL TEXT  

Control of Disease Attributable to Haemophilus influenzae Type b and the National Immunization Program
Meissner and Pickering
Pediatrics 2002;110:820-823.
FULL TEXT  

Antibody Avidity and Immunoglobulin G Isotype Distribution following Immunization with a Monovalent Meningococcal B Outer Membrane Vesicle Vaccine
Vermont et al.
Infect. Immun. 2002;70:584-590.
ABSTRACT | FULL TEXT  

Functional Antibody Activity Elicited by Fractional Doses of Haemophilus influenzae Type b Conjugate Vaccine (Polyribosylribitol Phosphate-Tetanus Toxoid Conjugate)
Romero-Steiner et al.
CVI 2001;8:1115-1119.
ABSTRACT | FULL TEXT  

Antibody Maturation in Trypanosoma cruzi-Infected Rats
Marcipar et al.
CVI 2001;8:802-805.
ABSTRACT | FULL TEXT  

Avidity, Potency, and Cross-Reactivity of Monoclonal Antibodies to Pneumococcal Capsular Polysaccharide Serotype 6B
Sun et al.
Infect. Immun. 2001;69:336-344.
ABSTRACT | FULL TEXT  

Relationship between Serum Bactericidal Activity and Serogroup-Specific Immunoglobulin G Concentration for Adults, Toddlers, and Infants Immunized with Neisseria meningitidis Serogroup C Vaccines
Sikkema et al.
CVI 2000;7:764-768.
ABSTRACT | FULL TEXT  

Immune Function and Vaccine Responses in Healthy Advanced Elderly Patients
Carson et al.
Arch Intern Med 2000;160:2017-2024.
ABSTRACT | FULL TEXT  

Avidity as a Determinant of the Protective Efficacy of Human Antibodies to Pneumococcal Capsular Polysaccharides
Usinger and Lucas
Infect. Immun. 1999;67:2366-2370.
ABSTRACT | FULL TEXT  

Haemophilus influenzae Type b Polysaccharides-Protein Conjugate Vaccine Elicits a More Diverse Antibody Repertoire in Infants Than in Adults
Adderson et al.
J. Immunol. 1998;161:4177-4182.
ABSTRACT | FULL TEXT  

Monoclonal Antibodies Reveal Additional Epitopes of Serotype D Cryptococcus neoformans Capsular Glucuronoxylomannan that Elicit Protective Antibodies
Mukherjee et al.
J. Immunol. 1998;161:3557-3568.
ABSTRACT | FULL TEXT  

A Modified Enzyme-Linked Immunosorbent Assay for Measurement of Antibody Responses to Meningococcal C Polysaccharide That Correlate with Bactericidal Responses
Granoff et al.
CVI 1998;5:479-485.
ABSTRACT | FULL TEXT  

Age-Dependent Neisseria meningitidis Serogroup C Class-Specific Antibody Concentrations and Bactericidal Titers in Sera from Young Children from Montana Immunized with a Licensed Polysaccharide Vaccine
Maslanka et al.
Infect. Immun. 1998;66:2453-2459.
ABSTRACT | FULL TEXT  

Aging and the Immune Response to the Haemophilus influenzae Type b Capsular Polysaccharide: Retention of the Dominant Idiotype and Antibody Function in the Elderly
Lucas and Reason
Infect. Immun. 1998;66:1752-1754.
ABSTRACT | FULL TEXT  

Use of Licensed Vaccines for Active Immunization of the Immunocompromised Host
Pirofski and Casadevall
Clin. Microbiol. Rev. 1998;11:1-26.
ABSTRACT | FULL TEXT